New drug cocktail aims to shrink tough lung cancers

NCT ID NCT07244926

Not yet recruiting Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a combination of two drugs—sacituzumab tirumotecan and bevacizumab—in 31 adults with advanced non-squamous lung cancer that has worsened after initial treatment. The goal is to see if the combo can shrink tumors or slow the disease. Participants receive the drugs intravenously every two weeks until the cancer progresses or side effects become too severe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sacituzumab tirumotecan (Sac-TMT) plus bevacizumab
What this could lead to: If successful, this combination could offer a new second-line treatment option for people with advanced non-squamous lung cancer who have no targetable gene changes.
What could go wrong: This is a small, early-phase trial with only 31 participants and no comparison group. The treatment may not work better than existing options and could cause side effects like infusion reactions or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

Contacts and locations

Locations

Tianjin Medical University Cancer Institute and Hospital

Tianjin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.